Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Health Center for Better Living warning letter

This article was originally published in The Tan Sheet

Executive Summary

Health Center for Better Living warning letter: Therapeutic claims for many of the Naples, Fla.-based firm's products cause them to be considered drugs rather than dietary supplements, FDA says in a warning letter. The agency lists the firm's Ginkgo Biloba with claims to treat Alzheimer's and senility, arthritis and rheumatism problems and lung and bronchial congestion; Coenzyme Q10, said to normalize blood pressure; Gout, which says it relieves gout pain; and Prime Lung, which makes claims for bronchitis, difficulty in breathing and chest pains. In addition, during the December 1995 inspection, sales representatives were overheard promoting shark cartilage for use in treating diseases such as cancer, diabetes and tumors, which, FDA says, are drug claims as well...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel